From yesterday’s Chromadex (sellers of Nicotinamide Riboside “NR” (FAQs) (Reviews)) earnings call:

Chromadex CEO Rob Fried:

“Since our last quarterly update, a number of preclinical trials have been completed that I want to highlight.

First, a recent preclinical study that was designed to assess the effectiveness of liposome based delivery of NR for treating cerebral ischemia.

The study utilized liposome encapsulated NR chloride given through IV injections in healthy mice and in cerebral ischemia model mice and examines its pharmacokinetics, organ distribution and therapeutic impact between the mice models.

The results demonstrated potential for NR liposomes for broader clinical application neuroprotective agents beyond standard stroke therapy.

A second preclinical study examined the impact of the combination of NR with resveratrol, the healing of diabetic ulcers caused by inflammation in a diabetic rat model.

Results highlighted the potential of NR and resveratrol in accelerating wound healing (an area Dr. Brenner is interested in).

Another preclinical study investigated the causes of miscarriages, congenital malformations, particularly the role of NAD deficiency using a mouse model.

Interestingly, researchers found that the risk of NAD deficiency is elevated during pregnancy and results suggest that a sufficient NAD supply is required to ensure normal embryonic development. Of course, further studies in human trials needed to validate these observations”

Related:

FOLLOW us on Twitter @RaisingNAD